First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the majority of patients. However, a couple of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccaluga, Pier Paolo, Paolini, Stefania, Bertuzzi, Clara, De Leo, Antonio, Rosti, Gianantonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514971/
https://www.ncbi.nlm.nih.gov/pubmed/23226701
http://dx.doi.org/10.2147/JBM.S13067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514971/
https://www.ncbi.nlm.nih.gov/pubmed/23226701
http://dx.doi.org/10.2147/JBM.S13067

Ejemplares similares